Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PSORAS
MCID: PSR001
MIFTS: 61

Psoriatic Arthritis (PSORAS)

Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Psoriatic Arthritis

About this section

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis 57 12 73 43 72 42 15 17
Psoriatic Arthritis, Susceptibility to 57 29 13 6
Arthropathic Psoriasis 12 43 32
Psoriatic Arthropathy 12 43 72
Arthritis, Psoriatic 44 70
Arthritis, Psoriatic, Susceptibility to 39
Psoriasis Arthropathica 72
Arthritis Psoriatica 12
Arthritic Psoriasis 72
Arthritis Psoriatic 54
Psoras 72

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:9008
OMIM® 57 607507
ICD9CM 34 696.0
MeSH 44 D015535
NCIt 50 C61277
SNOMED-CT 67 33339001
ICD10 32 L40.5
UMLS 70 C0003872
Sources

Summaries for Psoriatic Arthritis

About this section
MedlinePlus Genetics : 43 Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.Signs and symptoms of psoriatic arthritis include stiff, painful joints with redness, heat, and swelling in the surrounding tissues. When the hands and feet are affected, swelling and redness may result in a "sausage-like" appearance of the fingers or toes (dactylitis).In most people with psoriatic arthritis, psoriasis appears before joint problems develop. Psoriasis typically begins during adolescence or young adulthood, and psoriatic arthritis usually occurs between the ages of 30 and 50. However, both conditions may occur at any age. In a small number of cases, psoriatic arthritis develops in the absence of noticeable skin changes.Psoriatic arthritis may be difficult to distinguish from other forms of arthritis, particularly when skin changes are minimal or absent. Nail changes and dactylitis are two features that are characteristic of psoriatic arthritis, although they do not occur in all cases.Psoriatic arthritis is categorized into five types: distal interphalangeal predominant, asymmetric oligoarticular, symmetric polyarthritis, spondylitis, and arthritis mutilans.The distal interphalangeal predominant type affects mainly the ends of the fingers and toes. The distal interphalangeal joints are those closest to the nails. Nail changes are especially frequent with this form of psoriatic arthritis.The asymmetric oligoarticular and symmetric polyarthritis types are the most common forms of psoriatic arthritis. The asymmetric oligoarticular type of psoriatic arthritis involves different joints on each side of the body, while the symmetric polyarthritis form affects the same joints on each side. Any joint in the body may be affected in these forms of the disorder, and symptoms range from mild to severe.Some individuals with psoriatic arthritis have joint involvement that primarily involves spondylitis, which is inflammation in the joints between the vertebrae in the spine. Symptoms of this form of the disorder involve pain and stiffness in the back or neck, and movement is often impaired. Joints in the arms, legs, hands, and feet may also be involved.The most severe and least common type of psoriatic arthritis is called arthritis mutilans. Fewer than 5 percent of individuals with psoriatic arthritis have this form of the disorder. Arthritis mutilans involves severe inflammation that damages the joints in the hands and feet, resulting in deformation and movement problems. Bone loss (osteolysis) at the joints may lead to shortening (telescoping) of the fingers and toes. Neck and back pain may also occur.

MalaCards based summary : Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and psoriasis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Etanercept and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 An arthritis that is characterized by joint inflammation that usually occurs in combination with psoriasis.

OMIM® : 57 Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507) (Updated 05-Apr-2021)

MedlinePlus : 42 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

UniProtKB/Swiss-Prot : 72 Psoriatic arthritis: An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

Wikipedia : 73 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Sources

Related Diseases for Psoriatic Arthritis

About this section

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.1 TNFSF11 TNFRSF1B TNF NOD2 MMP3 HLA-B
2 psoriasis 32.4 TNFRSF1B TNF SELE S100A12 PTPN22 NOD2
3 juvenile rheumatoid arthritis 32.3 TNFRSF1B TNF S100A12 MMP3 LTA IL1B
4 arthritis 32.3 TNIP1 TNFSF11 TNFRSF1B TNF S100A12 PTPN22
5 spondylitis 32.2 TNFSF11 TNF NOD2 MICA LTA IL1B
6 uveitis 31.8 TNF NOD2 LTA IL1B HLA-B
7 synovitis 31.8 TNFSF11 TNF SELE MMP3 IL1B CRP
8 tenosynovitis 31.7 TNF NOD2 MMP3 IL1B CRP
9 arthropathy 31.7 TNFSF11 TNF MMP3 MICA LTA IL1B
10 skin disease 31.7 TNF SELE MIR146A IL1B IL13 HLA-C
11 fibromyalgia 31.6 TNF IL1B CRP
12 spondyloarthropathy 31.6 TNFSF11 TNF SELE MMP3 LTA IL1B
13 atherosclerosis susceptibility 31.6 TNF SELE IL1B CRP
14 spondylarthropathy 31.5 TNF HLA-B
15 exanthem 31.5 TNF IL1B CRP
16 osteoarthritis 31.4 TNFSF11 TNF MMP3 IL1B CRP COMP
17 herpes zoster 31.4 TNF HLA-DRB1 HLA-B
18 bone resorption disease 31.4 TNFSF11 TNF IL1B CRP
19 iridocyclitis 31.4 TNF IL1B HLA-B CRP
20 bursitis 31.3 TNF MMP3 IL1B CRP
21 reactive arthritis 31.3 TNF IL1B HLA-DRB1 HLA-B CRP COMP
22 spinal disease 31.3 TNF MIR146A IL1B CRP
23 psoriasis 1 31.3 TNIP1 MICA HLA-C HLA-B
24 vasculitis 31.2 TNF SELE HLA-B CRP
25 dermatitis 31.2 TNF NOD2 IL1B IL13
26 crohn's disease 31.2 TNFRSF1B TNF S100A12 PTPN22 NOD2 IL1B
27 lupus erythematosus 31.2 TNIP1 TNFRSF1B TNF PTPN22 HLA-DRB1
28 autoimmune disease 31.2 TNFRSF1B TNF PTPN22 MIR146A LTA IL1B
29 ulcerative colitis 31.1 TNF S100A12 NOD2 IL1B IL13 HLA-DRB1
30 pyoderma 31.1 TNF NOD2 IL1B CRP
31 diarrhea 31.1 TNF NOD2 IL1B IL13
32 tendinitis 31.1 TNF MMP3 IL1B CRP COMP
33 rheumatoid arthritis 31.1 TNIP1 TNFSF11 TNFRSF1B TNF SELE S100A12
34 crohn's colitis 31.1 TNF NOD2 IL1B
35 thyroiditis 31.1 TNF PTPN22 IL1B HLA-DRB1 CRP
36 osteoporosis 31.1 TNFSF11 TNFRSF1B TNF MMP3 IL1B CRP
37 pericarditis 31.0 TNF IL1B CRP
38 leishmaniasis 31.0 TNF IL1B IL13 HLA-DRB1
39 syphilis 31.0 TNF HLA-DRB1 HLA-C CRP
40 dermatitis, atopic 31.0 TNF SELE NOD2 LTA IL1B IL13
41 vascular disease 30.9 TNF SELE MMP3 MIR146A CRP
42 severe acute respiratory syndrome 30.9 TNF IL1B HLA-C CRP
43 proteasome-associated autoinflammatory syndrome 1 30.9 TNF SELE IL1B IL13 CRP
44 aortitis 30.9 TNF IL1B CRP
45 subacute thyroiditis 30.9 TNF IL1B CRP
46 conjunctivitis 30.9 TNF IL13 HLA-B
47 pneumonia 30.9 TNF IL1B IL13 CRP
48 bone disease 30.9 TNFSF11 TNF LTA IL1B COMP
49 body mass index quantitative trait locus 11 30.9 TNFRSF1B TNF SELE MMP3 MIR146A IL1B
50 aseptic meningitis 30.9 TNF IL1B CRP

Graphical network of the top 20 diseases related to Psoriatic Arthritis:



Diseases related to Psoriatic Arthritis
Sources

Symptoms & Phenotypes for Psoriatic Arthritis

About this section

Clinical features from OMIM®:

607507 (Updated 05-Apr-2021)

UMLS symptoms related to Psoriatic Arthritis:


back pain; sciatica; muscle cramp

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.68 MICA
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.68 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.68 MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.68 HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.68 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.68 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.68 SELE
8 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.68 HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.68 SELE
10 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.68 SELE
11 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.68 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.68 SELE
13 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.68 NOD2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.68 SELE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.68 SELE
16 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.68 MICA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.68 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.68 MICA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.68 HLA-B HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.68 MICA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.68 HLA-C

MGI Mouse Phenotypes related to Psoriatic Arthritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.44 COMP CRP IL13 IL1B LTA MMP3
Sources

Drugs & Therapeutics for Psoriatic Arthritis

About this section

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4 185243-69-0
2
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
3
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
4
Infliximab Approved Phase 4 170277-31-3
5
Brodalumab Approved, Investigational Phase 4 1174395-19-7
6
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Abatacept Approved Phase 4 332348-12-6 10237
9
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Vitamin B9 Phase 4
13 Folic Acid Antagonists Phase 4
14 Vitamin B Complex Phase 4
15 Immunosuppressive Agents Phase 4
16 Folate Phase 4
17 Dermatologic Agents Phase 4
18 Gastrointestinal Agents Phase 4
19 Antibodies, Monoclonal Phase 4
20 Immunologic Factors Phase 4
21 Anti-Bacterial Agents Phase 4
22 Angiogenesis Inhibitors Phase 4
23 Triamcinolone diacetate Phase 4
24 Triamcinolone hexacetonide Phase 4
25 triamcinolone acetonide Phase 4
26 Hormone Antagonists Phase 4
27 Hormones Phase 4
28 Adrenocorticotropic Hormone Phase 4
29 Melanocyte-Stimulating Hormones Phase 4
30 beta-Endorphin Phase 4
31 Rosuvastatin Calcium Phase 4 147098-20-2
32 Calcium, Dietary Phase 4
33
Calcium Nutraceutical Phase 4 7440-70-2 271
34
Lactitol Approved, Investigational Phase 3 585-86-4 157355
35
tannic acid Approved Phase 3 1401-55-4
36
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
37
Upadacitinib Approved, Investigational Phase 3 1310726-60-3 58557659
38
Tofacitinib Approved, Investigational Phase 3 477600-75-2
39
Ustekinumab Approved, Investigational Phase 3 815610-63-0
40
Ixekizumab Approved, Investigational Phase 3 1143503-69-8
41
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
42
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
43
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
44
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
45
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
46
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
47
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
48
Entecavir Approved, Investigational Phase 3 142217-69-4 153941
49
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
50 Phosphodiesterase 4 Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 386)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
3 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
4 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Completed NCT00573651 Phase 4
5 Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® Completed NCT00127842 Phase 4 Etanercept
6 A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL) Completed NCT02814175 Phase 4 methotrexate (MTX)
7 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks Completed NCT02798211 Phase 4 Secukinumab 300 mg;Secukinumab 150 mg
8 TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile Completed NCT00432406 Phase 4 Infliximab;Etanercept
9 A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis. Completed NCT00245960 Phase 4 etanercept
10 Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab? Completed NCT01465438 Phase 4 Adalimumab
11 A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive Completed NCT03151551 Phase 4 Ixekizumab;Adalimumab
12 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
13 Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice Completed NCT01147874 Phase 4
14 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
15 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
16 Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases Completed NCT00462072 Phase 4 Infliximab
17 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
18 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
19 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
20 A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD Recruiting NCT03747939 Phase 4 Apremilast (CC-10004)
21 A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) Monotherapy on MRI Outcomes in Subjects With Active Psoriatic Arthritis Recruiting NCT03783026 Phase 4 CC-10004
22 Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab Recruiting NCT03623867 Phase 4 Secukinumab;Placebo
23 Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study Recruiting NCT03797872 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Methylprednisolone;Triamcinolone
24 Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial. Recruiting NCT03739853 Phase 4 Methotrexate;Sulfasalazine;Leflunomide;Adalimumab
25 Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast Recruiting NCT04102449 Phase 4 Apremilast
26 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
27 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Recruiting NCT04106804 Phase 4 Abatacept 125 MG/ML
28 A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis Recruiting NCT03082729 Phase 4 Apremilast
29 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Active, not recruiting NCT03419650 Phase 4 ACTHar
30 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Enrolling by invitation NCT04515732 Phase 4 Apremilast Oral Tablet
31 SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE Not yet recruiting NCT04417114 Phase 4 Rosuvastatin
32 A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis Withdrawn NCT02558361 Phase 4 Treatment with Apremilast
33 A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis Unknown status NCT01860976 Phase 3 Abatacept;Placebo
34 Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis Unknown status NCT03191539 Phase 3 Apremilast
35 A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4) Completed NCT02294227 Phase 3
36 A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor Completed NCT01882439 Phase 3 Tofacitinib;Tofacitinib;Tofacitinib;Tofacitinib
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis Completed NCT01877668 Phase 3 Tofacitinib 5 mg BID;Tofacitinib 10 mg BID;Adalimumab;Placebo;Placebo
38 A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis Completed NCT01871649 Phase 3 golimumab;methotrexate
39 A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis Completed NCT01690299 Phase 3 Apremilast;Etanercept;Placebo tablet;Placebo injection
40 A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT01365455 Phase 3 secukinumab 150 mg;placebo to secukinumab 150 mg
41 MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs) Completed NCT02721966 Phase 3 Secukinumab and Placebo
42 A Randomised Controlled Trial to Compare Intensive Management vs Standard Care in Early Psoriatic Arthritis Completed NCT01106079 Phase 3 Intensive management or Tight control;Standard management - Control group
43 A Randomized, Multicenter, International, Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate (MTX) Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis Completed NCT00367237 Phase 3 Infliximab + methotrexate (IFX + MTX);Methotrexate (MTX)
44 A Multicenter, Randomized, Double-blind Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab) for the Treatment of Patients With Psoriatic Arthritis Completed NCT00051623 Phase 3 Infliximab
45 A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa MonoclonalAntibody, Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Completed NCT00265096 Phase 3
46 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Completed NCT03158285 Phase 3 Guselkumab;Placebo
47 A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis Completed NCT02986139 Phase 3 Commercial Formulation Etanercept;New Formulation Etanercept
48 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s) Completed NCT01077362 Phase 3 placebo;ustekinumab 45 mg;ustekinumab 90 mg
49 Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNFα) Therapy Completed NCT03796858 Phase 3 Guselkumab 100 mg;Placebo
50 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents Completed NCT03162796 Phase 3 Guselkumab;Placebo

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Auranofin
Aurothioglucose
Etanercept

Cochrane evidence based reviews: arthritis, psoriatic

Sources

Genetic Tests for Psoriatic Arthritis

About this section

Genetic tests related to Psoriatic Arthritis:

# Genetic test Affiliating Genes
1 Psoriatic Arthritis, Susceptibility to 29 LTA
Sources

Anatomical Context for Psoriatic Arthritis

About this section

MalaCards organs/tissues related to Psoriatic Arthritis:

40
Skin, Bone, T Cells, Endothelial, Thyroid, Liver, Eye
Sources

Publications for Psoriatic Arthritis

About this section

Articles related to Psoriatic Arthritis:

(show top 50) (show all 9387)
# Title Authors PMID Year
1
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6 57 61
12746914 2003
2
CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. 57 54 61
12879366 2003
3
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 61 54 57
12639988 2003
4
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. 61 57
18800148 2009
5
PSORS2 markers are not associated with psoriatic arthritis in the Italian population. 61 57
16733365 2006
6
A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. 61 57
12474146 2003
7
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 57 61
11841557 2002
8
HLA-C locus alleles in patients with psoriatic arthritis (PsA). 61 57
10321964 1999
9
Mild cognitive impairment in psoriatic arthritis: Prevalence and associated factors. 42 61
33725953 2021
10
The effects of IL-17/IL-17R inhibitors on atherosclerosis in psoriasis and psoriatic arthritis: A protocol for systematic review and meta analysis. 42 61
33578549 2021
11
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. 61 47
20500689 2010
12
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
13
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
14
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
15
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 6
14718719 2004
16
Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. 6
12426569 2002
17
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
18
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
19
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
20
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
21
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
22
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 6
10450718 1999
23
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
24
Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. 57
9347803 1997
25
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
26
Eruptive lentiginosis confined to areas of regressing psoriatic plaques after adalimumab treatment. 42
33272688 2021
27
Lipoma arborescens co-existing with psoriatic arthritis releases tumour necrosis factor alpha and matrix metalloproteinase 3. 54 61
20237127 2010
28
Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. 61 54
20415816 2010
29
The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. 54 61
19904485 2010
30
Infliximab and anterior optic neuropathy: case report and review of the literature. 54 61
19916016 2010
31
Possible association between NOD2 variants and joint surgery in psoriatic arthritis. 61 54
20346235 2010
32
Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. 61 54
19554022 2009
33
A case of tuberculous arthritis following the use of etanercept. 61 54
19949742 2009
34
Psoriatic arthritis: pharmacoeconomic considerations. 54 61
19691929 2009
35
Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? 61 54
19479708 2009
36
Spondyloarthropathies: Targeted therapy for psoriatic arthritis. 61 54
19412187 2009
37
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. 61 54
19188093 2009
38
Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. 61 54
19363860 2009
39
Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. 54 61
19505409 2009
40
Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? 54 61
19151120 2009
41
Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. 61 54
19016693 2009
42
Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. 54 61
19222252 2009
43
Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. 61 54
18986481 2008
44
Etanercept in therapy multiresistant overlapping pityriasis lichenoides. 61 54
19112768 2008
45
Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. 54 61
19036225 2008
46
Spinal epidural abscess associated with infliximab treatment for psoriatic arthritis. Case report. 61 54
18928222 2008
47
Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. 61 54
18694376 2008
48
Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. 61 54
20476959 2008
49
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. 61 54
18503600 2008
50
[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept]. 61 54
18210001 2008
Sources

Variations for Psoriatic Arthritis

About this section

ClinVar genetic disease variations for Psoriatic Arthritis:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TNF TNF, -308G-A SNV risk factor 12388 GRCh37:
GRCh38:
2 LTA , LOC100287329 NM_000595.4(LTA):c.-10+90A>G SNV risk factor 14380 rs909253 GRCh37: 6:31540313-31540313
GRCh38: 6:31572536-31572536
3 NOD2 NM_001370466.1(NOD2):c.1753G>A (p.Ala585Thr) SNV Uncertain significance 4700 rs104895438 GRCh37: 16:50745656-50745656
GRCh38: 16:50711745-50711745
4 NOD2 NM_001370466.1(NOD2):c.1970G>A (p.Arg657Gln) SNV Uncertain significance 779017 rs114664276 GRCh37: 16:50745873-50745873
GRCh38: 16:50711962-50711962
5 NOD2 NM_001370466.1(NOD2):c.2116G>A (p.Val706Met) SNV Uncertain significance 992540 GRCh37: 16:50746019-50746019
GRCh38: 16:50712108-50712108
6 NOD2 NM_001370466.1(NOD2):c.2782G>A (p.Val928Ile) SNV Likely benign 97869 rs5743291 GRCh37: 16:50757276-50757276
GRCh38: 16:50723365-50723365
Sources

Expression for Psoriatic Arthritis

About this section
Search GEO for disease gene expression data for Psoriatic Arthritis.
Sources

Pathways for Psoriatic Arthritis

About this section

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.72 TNFSF11 TNFRSF1B TNF S100A12 PTPN22 NOD2
2
PAK Pathway 63
Show member pathways
 13.26 TNFSF11 TNFRSF1B TNF PTPN22 LTA IL1B
3
Human cytomegalovirus infection 36
Show member pathways
 12.89 TNFRSF1B TNF MICA IL1B HLA-C HLA-B
4
Cytokine Signaling in Immune system 65
Show member pathways
 12.81 TNFSF11 TNFRSF1B TNF NOD2 MMP3 LTA
5
Measles 36
Show member pathways
 12.77 TNF IL1B HLA-DRB1 HLA-C HLA-B
6
Herpes simplex virus 1 infection 36
12.75 TNF LTA IL1B HLA-DRB1 HLA-C HLA-B
7
Th17 cell differentiation 36
Show member pathways
 12.55 TNF NOD2 IL1B IL13 HLA-DRB1
8
TRAF Pathway 63
Show member pathways
 12.5 TNIP1 TNFSF11 TNFRSF1B TNF LTA IL1B
9
Allograft rejection 1 36
Show member pathways
 12.5 TNF MICA LTA IL1B IL13 HLA-DRB1
10
NF-kappaB Signaling 4
12.47 TNIP1 TNFSF11 TNFRSF1B TNF PTPN22 IL1B
11
Human T-cell leukemia virus 1 infection 36
12.3 TNF LTA HLA-DRB1 HLA-C HLA-B
12
IL-17 Family Signaling Pathways 64
Show member pathways
 12.29 TNF MMP3 IL1B IL13
13
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.21 TNF LTA IL1B IL13 HLA-C HLA-B
14
Tuberculosis 36
12.19 TNF NOD2 IL1B HLA-DRB1
15
Phagosome 36
12.09 HLA-DRB1 HLA-C HLA-B COMP
16
Cell adhesion molecules 36
12.07 SELE HLA-DRB1 HLA-C HLA-B
17
NF-kappa B signaling pathway 36
11.89 TNFSF11 TNF LTA IL1B
18
Interleukin-4 and 13 signaling 65
11.86 TNFRSF1B TNF MMP3 IL1B IL13
19
TNF Superfamily Pathway: Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.76 TNFSF11 TNFRSF1B TNF LTA
20
Innate Lymphoid Cell Differentiation Pathways 64
11.74 TNF LTA IL1B IL13
21
Rheumatoid arthritis 36
11.73 TNFSF11 TNF MMP3 IL1B HLA-DRB1
22
Th1 Differentiation Pathway 64
Show member pathways
 11.72 TNF LTA IL1B
23
Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 23
Show member pathways
 11.69 TNFSF11 TNFRSF1B TNF
24
Lung fibrosis 1
11.62 TNF IL1B IL13
25
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.61 TNF SELE MMP3 IL1B
26
Transcription_NF-kB signaling pathway 23
11.54 TNFRSF1B TNF LTA
27
Cellular Transformation by HTLV1 63
Show member pathways
 11.51 TNFRSF1B TNF LTA
28
Malaria 36
11.46 TNF SELE IL1B COMP
29
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.45 TNFSF11 TNF IL1B
30
Interleukin-10 signaling 65
11.42 TNFRSF1B TNF IL1B IL13
31
African trypanosomiasis 36
11.34 TNF SELE IL1B
32
Development and heterogeneity of the ILC family 1
11.27 TNF IL1B IL13
33
TNF signaling pathway 36
11.22 TNFRSF1B TNF SELE NOD2 MMP3 LTA
34
Cytokines and Inflammatory Response 1
11.09 TNF IL1B IL13 HLA-DRB1
35
IL-9 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types 64
10.74 IL1B IL13
Sources

GO Terms for Psoriatic Arthritis

About this section

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 TNFSF11 TNFRSF1B TNF S100A12 MMP3 LTA
2 cell surface GO:0009986 9.73 TNF NOD2 MICA HLA-DRB1 HLA-C HLA-B
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DRB1 HLA-C HLA-B
4 extracellular space GO:0005615 9.44 TNFSF11 TNF SELE S100A12 MMP3 MIR146A
5 MHC class I protein complex GO:0042612 9.37 HLA-C HLA-B
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DRB1 HLA-C HLA-B

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.16 S100A12 PTPN22 NOD2 HLA-DRB1 HLA-C HLA-B
2 defense response to bacterium GO:0042742 9.99 TNF S100A12 NOD2 MICA
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF PTPN22 NOD2 HLA-DRB1
4 defense response GO:0006952 9.92 TNIP1 TNF NOD2 HLA-B
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 TNFSF11 TNF S100A12 NOD2 HLA-DRB1
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.89 TNFSF11 TNFRSF1B TNF LTA
7 defense response to Gram-positive bacterium GO:0050830 9.88 TNF NOD2 LTA CRP
8 cellular response to lipopolysaccharide GO:0071222 9.88 TNFRSF1B TNF NOD2 MIR146A IL1B
9 positive regulation of inflammatory response GO:0050729 9.87 TNIP1 TNF S100A12 IL1B
10 positive regulation of gene expression GO:0010628 9.87 TNFSF11 TNF PTPN22 MIR146A IL1B IL13
11 negative regulation of interleukin-6 production GO:0032715 9.86 TNF PTPN22 MIR146A
12 regulation of inflammatory response GO:0050727 9.86 TNIP1 TNF SELE NOD2
13 interferon-gamma-mediated signaling pathway GO:0060333 9.85 HLA-DRB1 HLA-C HLA-B
14 positive regulation of JNK cascade GO:0046330 9.85 TNFSF11 TNF NOD2 IL1B
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNFSF11 TNF S100A12 NOD2 IL1B
16 cytokine-mediated signaling pathway GO:0019221 9.85 TNFSF11 TNFRSF1B TNF MMP3 IL1B IL13
17 cellular response to organic cyclic compound GO:0071407 9.84 TNF NOD2 IL1B
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF NOD2 IL1B
19 positive regulation of interleukin-8 production GO:0032757 9.82 TNF NOD2 IL1B
20 positive regulation of phagocytosis GO:0050766 9.81 TNF NOD2 IL1B
21 antigen processing and presentation GO:0019882 9.8 HLA-DRB1 HLA-C HLA-B
22 positive regulation of interferon-gamma production GO:0032729 9.8 TNF PTPN22 LTA IL1B
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF PTPN22 IL1B
24 inflammatory response GO:0006954 9.76 TNIP1 TNFRSF1B TNF SELE S100A12 IL1B
25 positive regulation of MAP kinase activity GO:0043406 9.73 TNFSF11 TNF S100A12 NOD2
26 positive regulation of glial cell proliferation GO:0060252 9.71 TNF LTA IL1B
27 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.7 TNFRSF1B TNF IL1B
28 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL1B
29 regulation of neuroinflammatory response GO:0150077 9.69 TNFRSF1B MMP3
30 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
31 cellular response to muramyl dipeptide GO:0071225 9.67 PTPN22 NOD2
32 negative regulation of lipid storage GO:0010888 9.67 TNF CRP
33 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-C HLA-B
34 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.65 HLA-C HLA-B
35 vascular endothelial growth factor production GO:0010573 9.65 TNF IL1B
36 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
37 positive regulation of protein K63-linked ubiquitination GO:1902523 9.62 PTPN22 NOD2
38 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IL1B
40 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.58 TNF LTA
41 detection of bacterium GO:0016045 9.58 NOD2 HLA-DRB1 HLA-B
42 response to lipopolysaccharide GO:0032496 9.5 TNFRSF1B SELE PTPN22 NOD2 LTA IL1B
43 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.43 TNF NOD2 LTA
44 immune response GO:0006955 9.32 TNFSF11 TNFRSF1B TNF MICA LTA IL1B

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.43 HLA-DRB1 HLA-C HLA-B
2 TAP binding GO:0046977 9.16 HLA-C HLA-B
3 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF11 TNF LTA
4 cytokine activity GO:0005125 9.02 TNFSF11 TNF LTA IL1B IL13
Sources

Sources for Psoriatic Arthritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....